Experts meeting in Paris are hopeful with the AIDS vaccine, which has confirmed an efficacy of 30% of the 16,000 people studied. It is the best result of history in the investigation of this type of vaccines, which opens the door to finding a definitive protection against the HIV virus.
In the International Conference Aids Vaccine 2009, held in Paris, experts worldwide have highlighted that the Thai AIDS vaccine has proven a "modest efficiency" but evidence that there is hope of finding the ultimate protection against the HIV virus. So far it has achieved the best result in the history of vaccine research and will establish a roadmap for future research.
According to the results of a study published in "The New England Journal of Medicine" the treatment of this vaccine is a combination of a canary virus (not harmful to man, used as transport to reach defense cells several fragments of HIV) with VIHvax, which is a purified protein of HIV to generate antibodies, demonstrating an efficacy of almost 30% in the people studied.
For the study, the researchers conducted trials on 16,000 Thai volunteers aged 18 to 30, being essentially heterosexual men and women. In the trial, about half received the six doses of the vaccine in one year and the other group received a placebo. All of them were tested for HIV every six months for a period of three years.
This research showed that 51 people were infected in the vaccinated group compared to 74 in the placebo group. "Over time we will see what the true protective effect of the vaccine is," says Peruvian expert Juan Carlos Hurtado Negreiros, present at the international conference "Aids Vaccine 2009" in Paris, where the results of the study were shown. .